

To,

Date: 13.02.2024

1. BSE Limited P.J. Towers, Dalal Street, Mumbai-400 001	2. National Stock Exchange of India Limited Exchange plaza, C-1, Block G, Bandra Kurla Complex, Bandra, East, Mumbai-400051, Maharashtra
--	---

Dear Sir/Madam,

Unit: Ortin Laboratories Limited

Sub: Outcome of Board Meeting held on 13.02.2024

Ref: Our Company's letter dated 06.02.2024

With reference to the subject cited, this is to inform the Exchanges that at the meeting of the Board of Directors of Ortin Laboratories Limited held on Tuesday, 13.02.2024 at 4:00 p.m. at the Registered Office of the Company at D. No. 1-8-B4, Ground Floor, F3 HIG, Block-4, Street no. 3, Baghlingampally, Hyderabad — 500044, the following were considered and approved:

1. Unaudited financial results for the quarter ended 31.12.2023. (Enclosed)
2. Limited Review Report as per Regulation 33 of SEBI (LO&DR) Regulations, 2015 for the quarter ended 31.12.2023. (Enclosed).
3. Appointment of Mr. Pramod Dnyandeo Waghe as an Additional Director (Non-Executive Category) of the Company w.e.f. 13.02.2024.
4. Appointment of Mr. Shashikant Shankarrao Igave as an Additional Director (Non-Executive Category) of the Company w.e.f. 13.02.2024.
5. Name Change of the Company from Ortin Laboratories Limited to Ortin Global Limited subject to the approval of members in the ensuing General Meeting.



6. Addition of the objects pertaining to Health care and Pharma to the exiting main objects of the Company subject to the approval of members in the ensuing General Meeting.
7. Convening Extra-Ordinary General Meeting of the Company on Friday, 05th of April, 2024 through video conferencing/OAVM.


The meeting concluded at 05:20 p.m.

This is for the information and records of the Exchanges.

Thanking you.

Yours sincerely,

For Ortin Laboratories Limited



S. Murali Krishna Murthy
Managing Director
DIN: 00540632


MURALI
KRISHNA
MURTHY SANKA

Digitally signed by
MURALI KRISHNA
MURTHY SANKA
Date: 2024.02.13
17:38:31 +05'30'

Encl: as above

Disclosure under Reg. 30 of SEBI (Listing Obligations and Disclosure Requirements) 2015 related to appointment of the directors as mentioned below:

S. No	Particulars	Mr. Pramod Dnyandeo Waghe	Mr. Shashikant Shankarrao Igave
1.	Reason for Appointment/Resignation	Appointment	Appointment
2.	Date of Appointment/Cessation and terms of appointment	13.02.2024	13.02.2024
3.	Brief Profile (in case of appointment)	Mr. Pramod is a graduate and has a rich experience in administration	Visionary and strategic operation leader having experience of over 20 years for business transformation to inspire and lead the organization through digital transformation. Seasoned team builder focused on acquiring and developing high performing team leaders and fostering culture of excellence.
4.	Disclosure of relationships between directors	NIL	NIL
5.	Shareholding, if any in the company	NIL	NIL



STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31.12.23

Rupees In Lakhs

S No	Particulars	Quarter Ended				Nine Months Ended		Previous Year
		31.12.2023	30.09.2023	30.06.2023	31.12.2022	31.12.2023	31.12.2022	Ended
		Un Audited	Un Audited	Un Audited	Un Audited	Un Audited	Un Audited	31.03.2023
1	a) Net Sales / Income from Operations	13.61	25.97	157.09	115.68	196.67	456.38	602.03
2	b) Other Operating Income	0.07	0.57	0.28	1.13	0.92	1.28	4.20
3	Total Income (1+2)	13.68	26.54	157.37	116.81	197.59	457.66	606.23
4	Expenditure							
	a) Cost of Material Consumed	119.75	-6.22	111.35	87.37	224.88	345.99	389.24
	b) Employee Benefits Expenses	6.19	22.12	19.16	21.21	47.47	64.91	84.66
	c) changes in inventory	126.09	45.00	-40.54	-86.93	130.55	-98.19	-50.27
	d) Finance cost	14.13	15.04	11.42	9.90	40.59	27.94	39.64
	c) Depreciation	6.28	5.87	5.87	7.27	18.02	21.80	25.01
	d) Other Expenditure	21.86	55.27	48.55	33.09	125.68	85.44	126.33
	e) Total Expenses	294.31	137.08	155.81	71.91	587.20	447.89	614.61
5	Profit / (Loss) before Exceptional Items and tax (3-4)	-280.63	-110.54	1.56	44.90	-389.61	9.77	-8.38
6	Exceptional Items	0.11	0.00	0.00	0.00	0.11	0.00	2.67
7	Profit / (Loss) before tax (5-6)	-280.74	-110.54	1.56	44.90	-389.72	9.77	-11.05
8	Tax Expense							
	a) Current Tax	0.00	0.00	0.00	0.61	0.00	0.61	0.00
	b) Deferred Tax	-1.56	1.54	-0.08	-1.29	-0.10	-1.83	-1.69
9	Profit / (Loss) after tax for the period from continuing operations (7-8)	-279.18	-112.08	1.64	45.58	-389.62	10.99	-9.36
10	Other comprehensive income							
	(i) Items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	(ii) Tax on items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	(i) Items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	(ii) Income tax relating to items that will be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	0.00	0.00
		0.00	0.00	0.00	0.00	0.00	0.00	0.00
11	Total comprehensive income for the period (comprising Profit(Loss) and other comprehensive income for the period (9+10)	-279.18	-112.08	1.64	45.58	-389.62	10.99	-9.36
12	Paid-up equity share capital (Face value of Rs. 10/- per share)	813.14	813.14	813.14	813.14	813.14	813.14	813.14
13	Other Equity							273.35
14	Earnings Per Share (EPS)							
	a) Basic and diluted EPS before extraordinary items for the period, for the year to date and for the previous year (not to be annualised)	(3.43)	(1.38)	0.02	0.56	(4.79)	0.14	(0.12)
	b) Basic and diluted EPS after Extraordinary items for the period, for the year to date and for the previous year (not to be annualised)	(3.43)	(1.38)	0.02	0.56	(4.79)	0.14	(0.12)

Notes:

- The above results have been recommended by the Audit Committee and approved by the Board of Directors at their meeting held on 13th February, 2024.
- The financial results of the company have been prepared in accordance with Indian Accounting Standards (Ind AS) notified under the Companies (Indian Accounting Standards) Rules, 2015 as amended by the Companies (Indian Accounting Standards) (Amendment) Rules 2016.
- The figures for the quarter ended December 31, 2023, September 30, 2023, June 30, 2023 and December 31, 2022 are balancing figures between the un-audited figures in respect of the previous quarters and year to date figures upto the respective quarter for the respective periods which were subject to limited review.
- Previous period figures have been regrouped / rearranged wherever necessary, to make them comparable.
- The entire operations of the Company relate to only one segment hence segmental reporting as per Ind AS 108 is not applicable.
- The Statutory Auditors of the Company have carried out "Review" of the above un-audited financial results and their Report has been placed before the Board at the said Meeting as required under Regulation 33 of SEBI (LODR) Regulations, 2015.
- The Drugs Control Administration, Government of Telangana has cancelled the Manufacturing License of the Company vide their proceeding dated 03.07.2023 as the Company could not upgrade the manufacturing facilities, infrastructure and recruitment of expert technical team as per the provisions of Schedule - M of Drugs & Cosmetics Act 1940 & rules made there under. Hence the Company has stopped the production of medicines in its manufacturing unit.
- The Cash Credit with Karnataka Bank Limited has been freed by the bank due to non-submission of renewal documents by the Company. However the Company has made repayments to an extent of Rs. 50,00,000/- during January and February 2024 against the outstanding dues pertaining to the credit facility.
- The results are also available on the website of the Company www.ortinlabsindia.com

For and on Behalf of the Board of Directors
ORTIN LABORATORIES LIMITED


S.MURALI KRISHNA MURTHY
MANAGING DIRECTOR
(DIN: 00540632)

Place : Hyderabad
Date: 13.02.2024



MATHESH & RAMANA
CHARTERED ACCOUNTANTS

Independent Auditor's Limited Review Report on unaudited quarterly and year to date financial results of the Company

To The Board of Directors of Ortin Laboratories Limited

1. We have reviewed the accompanying statement of Unaudited Financial Results of Ortin Laboratories Limited ("the Company") for the quarter ended on 31st December, 2023 ("the statement"). This statement is the responsibility of the Company's Management and has been approved by the Company's Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. (a) *The Drugs Control Administration, Government of Telangana has cancelled the Manufacturing License of the Company vide their proceeding dated 03.07.2023 as the Company could not upgrade the manufacturing facilities, infrastructure and recruitment of expert technical team as per the provisions of Schedule – M of Drugs & Cosmetics Act 1940 & rules made there under. Hence the Company has stopped the production of medicines in its manufacturing unit.*

(b) *The Cash Credit with Karnataka Bank Limited has been freezed by the bank due to non-submission of renewal documents by the Company. However the Company has made repayments to an extent of Rs. 50,00,000/- during January and February 2024 against the outstanding dues pertaining to the credit facility.*

Our opinion is not modified in respect of this matter.


4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Our conclusion on the Statement is not modified in respect of the above matters.

Place: Hyderabad

Date: 13.02.2024

UDIN: 24026285BKBGNV6326



For **MATHESH & RAMANA**
CHARTERED ACCOUNTANTS

K. MATHESH REDDY

M.No: 026285 Partner

E-mail : matheshca@yahoo.co.in